title: [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
authors.forename: E F M
authors.initials: EF
authors.lastname: Wouters
authors.forename: D S
authors.initials: DS
authors.lastname: Postma
authors.forename: B
authors.initials: B
authors.lastname: Fokkens
authors.forename: W C
authors.initials: WC
authors.lastname: Hop
authors.forename: J
authors.initials: J
authors.lastname: Prins
authors.forename: A F
authors.initials: AF
authors.lastname: Kuipers
authors.forename: H R
authors.initials: HR
authors.lastname: Pasma
authors.forename: C A J
authors.initials: CA
authors.lastname: Hensing
authors.forename: E C
authors.initials: EC
authors.lastname: Creutzberg
mesh_terms: D000328:Adult; D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage* / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D000068298:Fluticasone; D000068297:Fluticasone-Salmeterol Drug Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
chemical_list: D000730:Androstadienes; D001993:Bronchodilator Agents; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D000068298:Fluticasone; D000420:Albuterol